Parents have been surprised by recent headlines highlighting that a growing number of doctors are warning against the use of older antihistamines. The warnings about diphenhydramine, the active ingredient in Benadryl, stem from safety and efficacy concerns. The Canadian Society of Allergy and Clinical Immunology released a statement in October recommending curbing the use of older first-generation antihistamines in both adults and children. Side effects from standard doses of Benadryl include sedation, cognitive impairment, and possible heart rhythm abnormalities. They said newer antihistamines, including Reactine, Aerius, and Claritin, are safer. The CSACI statement called on regulators to consider moving Benadryl and other first-generation antihistamines to behind the counter. But pharmacists say putting Benadryl behind the counter is not practical and won't resolve the safety concerns. Consumers would have to speak to a pharmacist, who could decline to provide the medication. But since the drug is approved by Health Canada and is well known to consumers, many could continue to push for it. Health Canada said products containing diphenhydramine meet the requirements and regulations of the Food and Drugs Act. The agency says that it continues to monitor scientific information as it evolves and would take action if regulations require a change.